{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:03:56Z","timestamp":1787051036610,"version":"build-2736575974"},"reference-count":46,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.3201\/eid2504.171630","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T17:41:38Z","timestamp":1551202898000},"page":"661-671","source":"Crossref","is-referenced-by-count":24,"title":["Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries"],"prefix":"10.3201","volume":"25","author":[{"given":"Jonathon R.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Sadatsafavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Kevin","family":"Elwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawziah","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2504.171630-201903151605-R1","unstructured":"World Health Organization. Framework towards tuberculosis elimination in low-incidence countries. Geneva: The Organization; 2014 [cited 2018 Mar 7]. http:\/\/www.who.int\/tb\/publications\/elimination_framework\/en\/"},{"key":"key-10.3201\/eid2504.171630-201903151605-R2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12916-016-0595-5","article-title":"The impact of migration on tuberculosis epidemiology and control in high-income countries: a review.","volume":"14","author":"Pareek","year":"2016","journal-title":"BMC Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R3","unstructured":"Public Health Agency of Canada. Canadian tuberculosis standards, 7th ed. Ottawa (ON): Government of Canada; 2014 [cited 2018 Mar 7]. https:\/\/www.canada.ca\/en\/public-health\/services\/infectious-diseases\/canadian-tuberculosis-standards-7th-edition.html"},{"key":"key-10.3201\/eid2504.171630-201903151605-R4","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America.","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"key-10.3201\/eid2504.171630-201903151605-R5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid2504.171630-201903151605-R6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1503\/cmaj.131025","article-title":"Screening immigrants for latent tuberculosis: do we have the resources?","volume":"186","author":"Campbell","year":"2014","journal-title":"CMAJ"},{"key":"key-10.3201\/eid2504.171630-201903151605-R7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40258-015-0183-4","article-title":"A systematic review of studies evaluating the cost utility of screening high-risk populations for latent tuberculosis infection.","volume":"13","author":"Campbell","year":"2015","journal-title":"Appl Health Econ Health Policy"},{"key":"key-10.3201\/eid2504.171630-201903151605-R8","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3201\/eid1809.120128","article-title":"Evaluation of immigrant tuberculosis screening in industrialized countries.","volume":"18","author":"Pareek","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid2504.171630-201903151605-R9","unstructured":"Institute of Medicine (US) Committee on the Elimination of Tuberculosis in the United States. Ending neglect: the elimination of tuberculosis in the United States. Geiter L, editor. Washington (DC): National Academies Press; 2000."},{"key":"key-10.3201\/eid2504.171630-201903151605-R10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1473-3099(01)00122-0","article-title":"Mandatory screening and treatment of immigrants for latent tuberculosis in the USA: just restraint?","volume":"1","author":"Coker","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid2504.171630-201903151605-R11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jval.2012.04.013","article-title":"Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20144.","volume":"15","author":"Karnon","year":"2012","journal-title":"Value Health"},{"key":"key-10.3201\/eid2504.171630-201903151605-R12","unstructured":"Statistics Canada. Report on the demographic situation in Canada: permanent and temporary immigration to Canada from 2012 to 2014. Ottawa (ON): Government of Canada; 2016 [cited 2018 Mar 7]. http:\/\/www.statcan.gc.ca\/pub\/91-209-x\/2016001\/article\/14615-eng.htm"},{"key":"key-10.3201\/eid2504.171630-201903151605-R13","unstructured":"Badar S, Ara\u00fajo T, Zwerling A, Pai M. BCG world atlas. 2nd edition. 2017 [cited 2018 Mar 7]. http:\/\/www.bcgatlas.org\/index.php"},{"key":"key-10.3201\/eid2504.171630-201903151605-R14","unstructured":"World Health Organization. UNICEF. WHO-UNICEF estimates of BCG coverage. Geneva: World Health Organization; 2017 [cited 2018 Mar 7]. http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/timeseries\/tswucoveragebcg.html"},{"key":"key-10.3201\/eid2504.171630-201903151605-R15","doi-asserted-by":"publisher","first-page":"E473","DOI":"10.1503\/cmaj.150011","article-title":"Domestic impact of tuberculosis screening among new immigrants to Ontario, Canada.","volume":"187","author":"Khan","year":"2015","journal-title":"CMAJ"},{"key":"key-10.3201\/eid2504.171630-201903151605-R16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40291-015-0135-6","article-title":"Latent tuberculosis infection screening in immigrants to low-incidence countries: a meta-analysis.","volume":"19","author":"Campbell","year":"2015","journal-title":"Mol Diagn Ther"},{"key":"key-10.3201\/eid2504.171630-201903151605-R17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/aje\/kwt246","article-title":"Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup.","volume":"179","author":"Shea","year":"2014","journal-title":"Am J Epidemiol"},{"key":"key-10.3201\/eid2504.171630-201903151605-R18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201308-1480OC","article-title":"Persistent latent tuberculosis reactivation risk in United States immigrants.","volume":"189","author":"Walter","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40291-014-0125-0","article-title":"A systematic review on TST and IGRA tests used for diagnosis of LTBI in immigrants.","volume":"19","author":"Campbell","year":"2015","journal-title":"Mol Diagn Ther"},{"key":"key-10.3201\/eid2504.171630-201903151605-R20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","article-title":"Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update.","volume":"149","author":"Pai","year":"2008","journal-title":"Ann Intern Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S1473-3099(17)30194-9","article-title":"Post-migration follow-up of migrants identified to be at increased risk of developing tuberculosis at pre-migration screening: a systematic review and meta-analysis.","volume":"17","author":"Chan","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid2504.171630-201903151605-R23","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"key-10.3201\/eid2504.171630-201903151605-R24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults.","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R25","doi-asserted-by":"publisher","first-page":"e0186778","DOI":"10.1371\/journal.pone.0186778","article-title":"Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada.","volume":"12","author":"Campbell","year":"2017","journal-title":"PLoS One"},{"key":"key-10.3201\/eid2504.171630-201903151605-R26","first-page":"560","article-title":"Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.","volume":"159","author":"Salpeter","year":"1993","journal-title":"West J Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R27","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial.","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","journal-title":"Bull World Health Organ"},{"key":"key-10.3201\/eid2504.171630-201903151605-R28","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1164\/rccm.200405-584PP","article-title":"Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.","volume":"170","author":"Reichman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R29","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1016\/S0140-6736(16)31008-X","article-title":"Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519\u2008955 migrants screened before entry to England, Wales, and Northern Ireland.","volume":"388","author":"Aldridge","year":"2016","journal-title":"Lancet"},{"key":"key-10.3201\/eid2504.171630-201903151605-R30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.","volume":"179","author":"Holland","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1164\/rccm.200408-1081OC","article-title":"Recurrent tuberculosis in the United States and Canada: relapse or reinfection?","volume":"170","author":"Jasmer","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R32","unstructured":"Statistics Canada. Life tables, Canada, provinces, and territories. 2016 [cited 2018 Mar 7]. http:\/\/www5.statcan.gc.ca\/olc-cel\/olc.action?objId=84-537-X&objType=2&lang=en&limit=0"},{"key":"key-10.3201\/eid2504.171630-201903151605-R33","first-page":"1414","article-title":"Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts.","volume":"12","author":"Marra","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2504.171630-201903151605-R34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF03405248","article-title":"Costs for tuberculosis care in Canada.","volume":"99","author":"Menzies","year":"2008","journal-title":"Can J Public Health"},{"key":"key-10.3201\/eid2504.171630-201903151605-R35","unstructured":"Statistics Canada. Consumer price index, annual average, not seasonally adjusted. 2019 [cited 2018 Mar 7]. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000501"},{"key":"key-10.3201\/eid2504.171630-201903151605-R36","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1524-4733.2008.00334.x","article-title":"Cost-effectiveness of LTBI treatment for TB contacts in British Columbia.","volume":"11","author":"Tan","year":"2008","journal-title":"Value Health"},{"key":"key-10.3201\/eid2504.171630-201903151605-R37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jpainsymman.2009.04.007","article-title":"Cost trajectories at the end of life: the Canadian experience.","volume":"38","author":"Fassbender","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"key-10.3201\/eid2504.171630-201903151605-R38","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s11136-014-0858-6","article-title":"The impact of tuberculosis on health utility: a longitudinal cohort study.","volume":"24","author":"Bauer","year":"2015","journal-title":"Qual Life Res"},{"key":"key-10.3201\/eid2504.171630-201903151605-R39","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1513\/AnnalsATS.201405-188OC","article-title":"Reproducibility of interferon gamma (IFN-\u03b3) release Assays. A systematic review.","volume":"11","author":"Tagmouti","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"key-10.3201\/eid2504.171630-201903151605-R40","doi-asserted-by":"publisher","first-page":"210","DOI":"10.7326\/0003-4819-126-3-199702010-00005","article-title":"Reliability of tuberculin skin test measurement.","volume":"126","author":"Pouchot","year":"1997","journal-title":"Ann Intern Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R41","doi-asserted-by":"publisher","first-page":"737","DOI":"10.5588\/ijtld.17.0019","article-title":"Capacity strengthening through pre-migration tuberculosis screening programmes: IRHWG experiences.","volume":"21","author":"Douglas","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2504.171630-201903151605-R42","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1164\/ajrccm.161.3.9902005","article-title":"Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis.","volume":"161","author":"Schwartzman","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R43","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMsa043194","article-title":"Domestic returns from investment in the control of tuberculosis in other countries.","volume":"353","author":"Schwartzman","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R44","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection.","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2504.171630-201903151605-R45","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1136\/bmj.316.7143.1529","article-title":"Perspectives in economic evaluation.","volume":"316","author":"Byford","year":"1998","journal-title":"BMJ"},{"key":"key-10.3201\/eid2504.171630-201903151605-R46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/oxfordjournals.aje.a112105","article-title":"Frost revisited: the modern epidemiology of tuberculosis.","volume":"101","author":"Comstock","year":"1975","journal-title":"Am J Epidemiol"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/25\/4\/17-1630_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:28:01Z","timestamp":1732987681000},"score":1,"resource":{"primary":{"URL":"http:\/\/wwwnc.cdc.gov\/eid\/article\/25\/4\/17-1630_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2504.171630","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}